Richard C. Malabre - 30 Jan 2026 Form 4 Insider Report for Akebia Therapeutics, Inc. (AKBA)

Role
SVP, Chief Accounting Officer
Signature
/s/ Carolyn M. Rucci, attorney-in-fact for Richard C. Malabre
Issuer symbol
AKBA
Transactions as of
30 Jan 2026
Net transactions value
$0
Form type
4
Filing time
03 Feb 2026, 16:37:42 UTC
Previous filing
11 Jun 2025
Next filing
04 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Malabre Richard C SVP, Chief Accounting Officer C/O AKEBIA THERAPEUTICS, INC, 245 FIRST ST., CAMBRIDGE /s/ Carolyn M. Rucci, attorney-in-fact for Richard C. Malabre 03 Feb 2026 0002007730

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AKBA Common Stock Award $0 +79,000 +29% $0.000000 348,914 30 Jan 2026 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AKBA Stock Option (Right to buy) Award $0 +119,000 $0.000000 119,000 30 Jan 2026 Common Stock 119,000 $1.41 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The restricted stock units were granted by the Issuer pursuant to its 2023 Stock Incentive Plan, as amended. One third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date, subject to the reporting person's continued service with the Issuer on each vesting date.
F2 Includes 1,500 shares of the Issuer's common stock purchased on June 30, 2025 and 1,500 shares of the Issuer's common stock purchased on December 31, 2025, each under the Issuer's Amended and Restated 2014 Employee Stock Purchase Plan.
F3 The options were granted by the Issuer pursuant to its 2023 Stock Incentive Plan, as amended. The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer on each vesting date.